Full Text
Full text is available in PDF
Conventional Interferon Alpha Therapy of Chronic Hepatitis C in Patients with End Stage Renal Disease, Six versus Twelve Months? A Meta-Analysis
Authors
1Research Center for Gastroenterology and Liver Disease,Baqiyatallah Research Center for Gastroenterology and Liver Diseases, [email protected], IR-Iran
2Research Center for Gastroenterology and Liver Disease,Baqiyatallah University of Medical Sciences, IR-Iran
*Corresponding Author: Research Center for Gastroenterology and Liver Disease,Baqiyatallah Research Center for Gastroenterology and Liver Diseases, [email protected], IR-Iran. Tel: +98- 21- 88067114. Fax: +98- 21- 88067114. Email: [email protected]
Published online:Jun 30, 2009
Article type:Review Article
How to Cite:Alavian S, Tabatabaei S. Conventional Interferon Alpha Therapy of Chronic Hepatitis C in Patients with End Stage Renal Disease, Six versus Twelve Months? A Meta-Analysis. Nephro-Urol Mon. 2009;1(1):. doi:
Abstract
Background and aims: Too many small studies have evaluated efficacy of standard interferon (IFN) in hemodialysis patients, however their findings are heterogeneous and absolute guideline for therapy is still unclear. In current review, we aim to determine which of 24 or 48 week of treatment has greater value in treatment of end stage renal disease in pre-transplantation patients.
Methods: We required that studies report HCV RNA results at least 6 months after treatment cessation. Ninety-five percent confidence intervals (CI) of SVRs were calculated using the approximate normal distribution model. 95% CI of pooled SVR was computed by random effects models. Data manipulation and statistical analyses were undertaken using STATA 8.0.
Results: The pooled SVR for 24 and 48 weeks of standard IFN monotherapy was 38.2% (95% CI=28.9%-47.5%) and 36.9% (95% CI=24.3%-49.4%), respectively. Pooled dropout rate was 24.2% (95% CI=9.5%-38.9%) and 26.9% (95% CI=10.6%-43.3%) in 24 and 48 weeks of IFN monotherapy, respectively.
Conclusion: Standard IFN is still the drug of choice in treatment of HCV in dialysis individuals and 6 months seems to be equal to one-year duration of therapy.
Highlights
Copyright
© 2009, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Similar Articles
31
Jan
2011
Ribavirin Combination Therapy of Chronic Hepatitis C Patients with End Stage Renal Disease: Review of Evidences on Efficacy and Safety
Seyed Moayed Alavian,
Vahid Tabatabaee,
Kamran Bagheri Lankarani
Alavian S, Tabatabaee V, Lankarani K. Ribavirin Combination Therapy of Chronic Hepatitis C Patients with End Stage Renal Disease: Review of Evidences on Efficacy and Safety. Nephro-Urol Mon. 2011;3(1):. doi:
18
Apr
2021
The Efficacy and Safety of Sofosbuvir/Daclatasvir Fixed-Dose Combination in Iranian Hemodialysis Patients with Hepatitis C Virus Infection
Kasra Ghanaat,
Heidar Sharafi,
Seyed Moayed Alavian
Ghanaat K, Sharafi H, Alavian SM. The Efficacy and Safety of Sofosbuvir/Daclatasvir Fixed-Dose Combination in Iranian Hemodialysis Patients with Hepatitis C Virus Infection. Nephro-Urol Mon. 2021;13(2):e114049. doi: https://doi.org/10.5812/numonthly.114049
12
Nov
2016
Successful Treatment of Acute Hepatitis C Virus (HCV) Infection with Interferon-Free Regimen in a Renal Transplant Patient: The First Case Report
Nawfal R Hussein,
Zana Sidiq Mohammed Saleem
Hussein NR, Saleem ZSM. Successful Treatment of Acute Hepatitis C Virus (HCV) Infection with Interferon-Free Regimen in a Renal Transplant Patient: The First Case Report. Int J Infect. 2017;4(4):e43268. doi: https://doi.org/10.17795/iji-43268
1
Jan
2015
Efficacy of 24-Week Pegylated Interferon Alpha and Ribavirin Combination Therapy in Highly Selected Patients Infected With Hepatitis C Virus Genotype 1
Heidar Sharafi,
Seyed Moayed Alavian,
Maryam Keshvari
Sharafi H, Alavian SM, Keshvari M. Efficacy of 24-Week Pegylated Interferon Alpha and Ribavirin Combination Therapy in Highly Selected Patients Infected With Hepatitis C Virus Genotype 1. Hepat Mon. 2015;15(1):e24955. doi: https://doi.org/10.5812/hepatmon.24955
1
Jan
2006
Preliminary Report of Interferon ?2b in Combination with Ribavirin for 48 Weeks for Treatment of Iranian Patients with Chronic Hepatitis C: a Quasi-Experimental Study
SM Alavian,
A Kabir,
B Hajarizadeh,
M Nayebpour,
T Dorodi,
FE Baralle
Alavian S, Kabir A, Hajarizadeh B, Nayebpour M, Dorodi T, et al. Preliminary Report of Interferon ?2b in Combination with Ribavirin for 48 Weeks for Treatment of Iranian Patients with Chronic Hepatitis C: a Quasi-Experimental Study. Shiraz E-Med J. 2006;7(1):20390. doi:
Cited by
- Scopus by DOI: 0
Last Update: 4 days ago
- Scopus by Title: 0
Last Update: 4 days ago
- Scopus by Title (Ref): 2
Last Update: 4 days ago
- CrossRef: 0
Last Update: 1 day ago
Comments
Number of Comments:0